Extended Data Fig. 2: Genomic analyses of primary and metastases.

a. Comparison of primary tumour and metastasis purity (median purity: primary = 0.43, primary LN/satellite = 0.32, recurrence/progression = 0.31, Wilcoxon rank-sum test), b. Comparison of primary tumour and metastasis ploidy (median ploidy: primary = 3.1, primary LN/satellite = 2.95, recurrence/progression = 3.1, Wilcoxon rank-sum test) c. Comparison of primary tumour and metastasis weighted genomic instability index (wGII, median wGII: primary = 0.53, primary LN/satellite = 0.52, recurrence/progression = 0.51, Wilcoxon rank-sum test) d. Comparison of primary tumour and metastasis fraction of the genome subject to loss of heterozygosity (FLOH, median FLOH: primary = 0.28, primary LN/satellite = 0.28, recurrence/progression = 0.32, Wilcoxon rank-sum test) e. Comparison of primary tumour and metastasis tumour mutation burden (TMB, median TMB: primary = 508, primary LN/satellite = 479, recurrence/progression = 651, Wilcoxon rank-sum test). f. Comparison of whole genome doubling (WGD) status between primary tumours and paired metastases. There is no enrichment in WGD in metastases (Fisher’s exact test, p = 1). The box plots represent the upper and lower quartiles (box limits), the median (centre line) and the vertical bars span the 5th to 95th percentiles. All tests were two-sided unless otherwise specified.